THERAPY-RELATED ACUTE MYELOID LEUKEMIA
Clinical trials for THERAPY-RELATED ACUTE MYELOID LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new THERAPY-RELATED ACUTE MYELOID LEUKEMIA trials appear
Sign up with your email to follow new studies for THERAPY-RELATED ACUTE MYELOID LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising combo aims to stop AML from coming back
Disease control OngoingThis study tests whether a combination of two chemotherapy drugs, azacitidine and venetoclax, can help keep acute myeloid leukemia (AML) in remission and prevent it from returning. About 50 adults whose AML is in remission after initial treatment and who are not ready for a stem …
Matched conditions: THERAPY-RELATED ACUTE MYELOID LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 17, 2026 05:54 UTC
-
New combo therapy shows promise for Tough-to-Treat leukemia
Disease control OngoingThis study tests a new drug called pevonedistat alongside standard chemotherapy for people with high-risk acute myeloid leukemia (AML). The goal is to see if the combination is safe and works better at putting the cancer into remission. About 53 adults with certain types of high-…
Matched conditions: THERAPY-RELATED ACUTE MYELOID LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 16, 2026 12:51 UTC
-
Promising combo aims to stop leukemia relapse after transplant
Disease control OngoingThis study tests whether two drugs, venetoclax and azacitidine, can help prevent leukemia from returning in 100 adults who have already had a stem cell transplant. Participants have high-risk acute myeloid leukemia (AML) or related blood cancers and are in remission after transpl…
Matched conditions: THERAPY-RELATED ACUTE MYELOID LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 12, 2026 12:05 UTC
-
New drug combo shows promise for Tough-to-Treat leukemia in younger patients
Disease control OngoingThis study tests a chemotherapy drug called CPX-351 in people under 60 with secondary acute myeloid leukemia (AML), a type of leukemia that develops after other blood disorders or cancer treatments. The goal is to see how well the drug can make the cancer disappear or improve blo…
Matched conditions: THERAPY-RELATED ACUTE MYELOID LEUKEMIA
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 10, 2026 13:29 UTC